Innovative breakthroughs, shaping new advantages; integration and optimization, striving for a hundred years
Release time:
2020-08-14
Innovation Breakthrough and Shaping New Advantages; Integration and Optimization, Endeavour Centennial Road
-Chairman's Message
Spring Festival is coming, we are about to enter the Year of the Dog in 1898, and our Jianfeng Group will also enter the 60th year since its inception. The past sixty years, is our peak forge ahead in sixty years, the continuous development and growth of sixty years. Especially since the reform and opening up, we have boldly explored, through measures such as alliances with township enterprises, stock issuance, cross-industry development, cooperation with central enterprises, transformation and upgrading, etc., we have blazed a path that everyone has never walked, and we have also written our peak 60 years. The glory of the year. This is not only a history of struggle, but also a history of innovation, but also a glorious history of the continuous progress of peak people.
Innovation Master Xiong Peter (Joseph Alois Schumpeter ) once said: Any technological transformation, process reengineering, management improvement, and process optimization belong to the category of innovation. With the development of science and technology, AI has become a reality from an assumption; the rise of emerging industries such as information technology and e-commerce has changed people's traditional thinking mode and way of life. New changes are taking place in the world every day, and the source of this change is "innovation". The world is not what it used to be, and the peak is not what it used to be. It is precisely because of our persistence in continuous innovation that we have flourished in the past 60 years. Innovation requires passion, courage and wisdom. In the future, we still need to continue to innovate in order to make the peak stand firm, continue to be strong, and move towards higher and farther goals.
Comrades, the convening of the 19th National Congress of the Communist Party of China marks that Chinese society has entered a new era. The development of enterprises is undergoing kinetic energy conversion, from high-speed growth to high-quality development. In today's era, the only constant is "change", "survival of the fittest" is the eternal truth. After these years of development, our cement has made extraordinary achievements in industrial layout, technological innovation, and technological transformation of facilities; our medicine has made gratifying achievements in plate layout and product research and development, but in the face of the new era, we will still face great challenges in the Red Sea market. Sixty years of a Jiazi, in the year of the opening of a Jiazi under the peak, we will use advanced strategies, bold innovations, and self-revolution to forge our century-old road. On the road of future development, we should use the wisdom of peak people and persist in continuous innovation to create new advantages; we should keep up with the pace of the development of cement in the world, strengthen ourselves through continuous learning, use advanced technological concepts, and take high-quality development as the main line to enhance the sustainable competitive advantage of our cement and add vitality to the traditional industry; our pharmaceutical industry, based on raw materials, chemical pharmaceuticals, and traditional Chinese medicine, combined with the evolution of the modern disease spectrum, it will play a greater role in tumor pharmaceuticals, infant medicines, and elderly medicines, and do a good job in the "smile curve" of products developed and sold at both ends. In the new year, we will increase investment in the construction of API bases and international generic drug bases, further integrate and optimize new drug research and development, production and sales, and accelerate the development of existing clinical and preclinical series of innovative drugs. The speed of research and development, with customer value and customer needs as our work goals, continuously improve the level of preparations, continuously accelerate the speed of research and development, and continuously improve the quality of drugs. The requirements for the full coverage of the consistency evaluation of domestic preparations have been clear. Only by making truly high-quality and effective products can we win the future and the market.
On the journey of "creating a century-old peak", we will inherit and carry forward the peak spirit of "unity and struggle, truth-seeking and innovation, determination to rise to the top, and bravely climb the peak"; we must "innovation, performance, integrity, Responsibility, tolerance" values to arm our employees. We should take excellent enterprises with excellent performance, leading technology, first-class management, well-known brand and core competitiveness as our ultimate goal; we should enhance the core competence of enterprises with innovative mechanism, optimize the layout, enhance the market competitiveness, and enhance the organizational competitiveness through integration and optimization. In this way, there is hope for our peak, and there is hope for our future. "Hundred years of peak" is not a dream!
"Xiongguan Mandao is really like iron, and now we are striding forward from the beginning". Today, we stand at a new historical starting point with the peak cause. Let's make positive progress and forge ahead with the peak 100-year road!
Chairman of Jianfeng Group Jiang Xiaomeng
February 7, 2018
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page